XY Capital Ltd Trims Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

XY Capital Ltd reduced its position in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 1.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 162,702 shares of the company’s stock after selling 1,784 shares during the quarter. Takeda Pharmaceutical makes up about 1.0% of XY Capital Ltd’s portfolio, making the stock its 10th largest position. XY Capital Ltd’s holdings in Takeda Pharmaceutical were worth $2,154,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of TAK. FMR LLC grew its stake in Takeda Pharmaceutical by 10.9% during the third quarter. FMR LLC now owns 2,908,918 shares of the company’s stock worth $41,365,000 after purchasing an additional 286,052 shares during the period. Stifel Financial Corp grew its stake in Takeda Pharmaceutical by 103.9% during the third quarter. Stifel Financial Corp now owns 440,666 shares of the company’s stock worth $6,266,000 after purchasing an additional 224,594 shares during the period. Summit Global Investments grew its stake in Takeda Pharmaceutical by 86.0% during the third quarter. Summit Global Investments now owns 415,558 shares of the company’s stock worth $5,909,000 after purchasing an additional 192,143 shares during the period. Crossmark Global Holdings Inc. grew its stake in Takeda Pharmaceutical by 284.9% during the fourth quarter. Crossmark Global Holdings Inc. now owns 210,484 shares of the company’s stock worth $2,787,000 after purchasing an additional 155,795 shares during the period. Finally, Van ECK Associates Corp grew its stake in Takeda Pharmaceutical by 6.6% during the third quarter. Van ECK Associates Corp now owns 2,175,236 shares of the company’s stock worth $30,149,000 after purchasing an additional 134,407 shares during the period. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Down 0.5 %

NYSE TAK opened at $13.54 on Monday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. The business has a 50 day simple moving average of $13.30 and a 200 day simple moving average of $13.88. The stock has a market capitalization of $43.08 billion, a P/E ratio of 33.85, a P/E/G ratio of 0.24 and a beta of 0.51. Takeda Pharmaceutical Company Limited has a one year low of $12.57 and a one year high of $15.08.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Thursday, January 30th. The company reported $0.42 EPS for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. Research analysts expect that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.